GO:0033132 negative regulation of glucokinase activity: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033132 (negative regulation of glucokinase activity) describes any process that stops, prevents, or reduces glucokinase (GCK) catalytic activity, the ATP-dependent phosphorylation of glucose.
• Glucokinase activity is controlled at multiple levels: transcriptional repression of the GCK gene, post-translational inhibition of the enzyme, and modulation by interacting proteins such as Hmbox1 [1, 2, 5].
• Hepatic glucokinase is a central node linking nutrient status to insulin sensitivity, and its dysregulation is implicated in nonalcoholic fatty liver disease and type 2 diabetes [2, 5].
• MODY2 mutations, including those in the nuclear export signal of glucokinase, alter enzyme localization and activity, providing direct genetic evidence for GCK regulation in disease.
• Natural compounds such as berberine and transcription factors including HNF4alpha, LXRalpha, SREBP-1c, and KLF6 regulate glucokinase expression and activity in hepatocytes [2, 5, 7].
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of negative regulators of glucokinase activity in metabolic and cardiovascular disease [1, 6].
Description
Glucokinase (GCK) catalyzes the ATP-dependent phosphorylation of glucose to glucose-6-phosphate, a rate-limiting step in glucose utilization and a critical sensor of glucose homeostasis. The Gene Ontology term GO:0033132, negative regulation of glucokinase activity, captures any process that stops, prevents, or reduces the frequency, rate, or extent of this catalytic activity. Because glucokinase activity determines how cells and organisms handle glucose, its negative regulation is central to metabolic physiology and disease [2, 5].
negative regulation of glucokinase activity At A Glance
| GO ID | GO:0033132 |
|---|---|
| GO term | negative regulation of glucokinase activity |
| Ontology | biological_process |
| Synonym | down regulation of glucokinase activity; down-regulation of glucokinase activity; downregulation of glucokinase activity; glucokinase inhibitor; inhibition of glucokinase activity |
| Major function | Reduces the ATP-dependent phosphorylation of glucose by glucokinase, thereby limiting glucose-6-phosphate formation |
| Regulated entity | Glucokinase (GCK), also known as hexokinase IV [1, 6] |
| Key tissues | Liver, pancreatic beta cells, cardiomyocytes [1, 2, 5] |
| Disease relevance | Nonalcoholic fatty liver disease, type 2 diabetes, ischemia/reperfusion injury [1, 2, 6] |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, enzyme activity assays, RNA-seq [1, 6] |
What Is GO:0033132?
GO:0033132 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of glucokinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a glucose molecule. In practice, this includes transcriptional repression of GCK, post-translational inhibition of the enzyme, and protein-protein interactions that lower glucokinase catalytic output [1, 2, 5].
Why Is negative regulation of glucokinase activity Important in Cell Biology?
Negative regulation of glucokinase activity is important because glucokinase sets the rate of glucose phosphorylation in hepatocytes and pancreatic beta cells, and its dysregulation contributes to metabolic disease [2, 5]. Understanding how GCK activity is restrained provides mechanistic insight into insulin sensitivity, hepatic glucose production, and cellular survival under stress [1, 2].
• Glucokinase activity is a rate-limiting determinant of hepatic glucose uptake and glycogen synthesis [2, 3].
• Negative regulation of GCK protects cells from excessive glucose flux under nutrient-rich conditions.
• Loss of GCK inhibition is linked to nonalcoholic fatty liver disease and insulin resistance.
• MODY2 mutations in GCK, including nuclear export signal variants, alter enzyme regulation and cause monogenic diabetes.
• Hmbox1 inhibition activates Gck and promotes cardiomyocyte survival in ischemia/reperfusion injury.
• Transcriptional regulators such as KLF6, LXRalpha, SREBP-1c, and HNF4alpha modulate GCK expression [2, 5, 7].
• Fatty acids regulate hepatocyte gene expression, including glucokinase, linking diet to GCK control.
• Protein kinase C beta signaling influences hepatic glycogen synthesis and intersects with glucokinase regulation.
• Crotonylation of metabolic enzymes regulates carbon catabolite repression, illustrating post-translational control of glucose metabolism.
• CRISPR models enable causal testing of negative regulators of glucokinase activity in disease contexts [1, 6].
What Happens During negative regulation of glucokinase activity?
Transcriptional repression of GCK
In simple terms: The cell makes less glucokinase mRNA, so less enzyme is available to phosphorylate glucose.
Negative regulation of glucokinase activity can occur at the transcriptional level, where transcription factors and nuclear receptors repress GCK gene expression. KLF6 links glucokinase to hepatic insulin sensitivity in nonalcoholic fatty liver disease, and its modulation affects GCK levels. The interplay between LXRalpha, SREBP-1c, PPARgamma, and small heterodimer partner regulates glucokinase gene expression in liver. HNF4alpha also influences glucokinase activity in primary hepatocytes.
Post-translational inhibition of glucokinase
In simple terms: The enzyme is made but its activity is switched down by modifications or interacting proteins.
Glucokinase activity can be reduced after translation through protein-protein interactions and post-translational modifications. Hmbox1 inhibition promotes Gck activation in cardiomyocytes, indicating that Hmbox1 restrains GCK under baseline conditions. Crotonylation of key metabolic enzymes regulates carbon catabolite repression, demonstrating that lysine acylation can control glucose-metabolizing enzyme activity.
Nutrient and hormonal control
In simple terms: What the cell eats and the hormones it sees determine how much glucokinase activity is allowed.
Fatty acids regulate human hepatocyte gene expression, including glucokinase, linking lipid availability to GCK control. Hepatic PKCbeta participates in nutritional regulation of hepatic glycogen synthesis, a pathway downstream of glucokinase. These inputs tune negative regulation of glucokinase activity to the organism's metabolic state [3, 4].
Compartmentalization and nuclear export
In simple terms: Where glucokinase sits inside the cell affects whether it can work.
MODY2 mutations in the nuclear export signal of glucokinase alter its functional behavior, showing that subcellular localization contributes to regulation of GCK activity. This compartmental control adds a layer to negative regulation beyond expression and catalysis.
Key Genes Involved in GO:0033132 negative regulation of glucokinase activity
The following genes and proteins are experimentally implicated in the negative regulation of glucokinase activity or in the pathways that control it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCK | Encodes glucokinase, the enzyme whose activity is negatively regulated [1, 6] | Core target for activity assays and MODY2 mutation studies |
| Hmbox1 | Restrains Gck activation in cardiomyocytes | Knockdown promotes cardiomyocyte survival and glucose metabolism |
| KLF6 | Links glucokinase to hepatic insulin sensitivity | Modulates GCK in nonalcoholic fatty liver disease |
| LXRalpha | Nuclear receptor regulating glucokinase gene expression | Part of the transcriptional network controlling GCK |
| SREBP-1c | Transcription factor in glucokinase gene regulation | Integrates lipogenesis and glucose metabolism |
| PPARgamma | Nuclear receptor in GCK transcriptional regulation | Therapeutic target in metabolic disease |
| SHP | Small heterodimer partner repressing GCK expression | Negative regulator in liver |
| HNF4alpha | Transcription factor affecting glucokinase activity | Berberine modulates HNF4alpha and GCK in hepatocytes |
| PKCbeta | Kinase in nutritional regulation of hepatic glycogen synthesis | Links signaling to glucose storage downstream of GCK |
| INS | Insulin, a hormonal input to hepatic glucose metabolism | Context for insulin sensitivity studies |
| PPARG | Peroxisome proliferator-activated receptor gamma | Transcriptional regulator in liver |
| NR0B2 | Encodes small heterodimer partner | Repressor of GCK expression |
| SREBF1 | Encodes SREBP-1c | Lipogenic transcription factor |
| NR1H3 | Encodes LXRalpha | Nuclear receptor in GCK regulation |
| KLF6 | Kruppel-like factor 6 | Hepatic insulin sensitivity link |
| GCKR | Glucokinase regulatory protein, a known GCK inhibitor | Classic negative regulator of glucokinase activity |
| HNF1A | Transcription factor in beta-cell glucose sensing | Context for monogenic diabetes |
| HNF4A | Hepatocyte nuclear factor 4 alpha | Regulates GCK in hepatocytes |
How Is negative regulation of glucokinase activity Regulated?
Negative regulation of glucokinase activity is itself regulated by nutrient and hormonal signals. Fatty acids alter hepatocyte gene expression, including glucokinase, and PKCbeta mediates nutritional control of hepatic glycogen synthesis. Nuclear receptors and transcription factors such as LXRalpha, SREBP-1c, PPARgamma, SHP, KLF6, and HNF4alpha form a transcriptional network that sets GCK expression levels [2, 5, 7]. Post-translational mechanisms, including crotonylation of metabolic enzymes, add another layer of control. In cardiomyocytes, Hmbox1 restrains Gck, and its inhibition activates glucose metabolism.
negative regulation of glucokinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCK | MODY2 monogenic diabetes | Knock-in of patient MODY2 mutations in beta cells |
| Hmbox1 | Ischemia/reperfusion injury in cardiomyocytes | Knockout or knockdown in cardiomyocyte lines |
| KLF6 | Nonalcoholic fatty liver disease and insulin resistance | Hepatocyte knockout and overexpression |
| HNF4A | Hepatic glucose metabolism | Primary hepatocyte knockdown |
| PKCbeta | Hepatic glycogen synthesis | Liver-specific knockout models |
Nonalcoholic fatty liver disease and insulin resistance
Glucokinase links KLF6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease, and dysregulated GCK activity contributes to impaired glucose handling. Transcriptional regulators including LXRalpha, SREBP-1c, PPARgamma, and SHP further connect GCK control to hepatic lipid and glucose metabolism.
Monogenic diabetes (MODY2)
MODY2 mutations in the nuclear export signal of glucokinase alter its functional properties, demonstrating that inherited changes in GCK regulation cause monogenic diabetes. These mutations provide direct human genetic evidence for the importance of glucokinase activity control.
Ischemia/reperfusion injury
Inhibition of Hmbox1 promotes cardiomyocyte survival and glucose metabolism through Gck activation in ischemia/reperfusion injury, showing that relieving negative regulation of glucokinase activity can be cardioprotective.
Metabolic regulation by natural compounds
Berberine affects HNF4alpha expression and glucokinase activity in mouse primary hepatocytes, illustrating that pharmacological modulation of GCK regulation has therapeutic potential.
From negative regulation of glucokinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate repressor increase glucokinase activity? | CRISPR knockout in hepatocyte or cardiomyocyte lines |
| Does a MODY2 mutation alter GCK regulation? | Point-mutation knock-in of the patient variant |
| Does a specific phosphorylation site control GCK inhibition? | Phospho-null or phospho-mimetic knock-in |
| Can a tagged GCK be used to measure protein interactions? | Tagged knock-in for immunoprecipitation |
| Does overexpression of a repressor lower glucose phosphorylation? | Doxycycline-inducible overexpression |
| Which transcriptional regulators bind the GCK promoter? | CRISPR knockout of LXRalpha, SREBP-1c, PPARgamma, or SHP |
How to Study the negative regulation of glucokinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glucokinase activity assay | Rate of glucose phosphorylation | Quantify negative regulation in lysates |
| RNA-seq | GCK and regulator transcript levels [2, 5] | Transcriptional repression studies [2, 5] |
| Western blot | GCK protein abundance and modifications | Post-translational regulation |
| Immunoprecipitation | GCK protein-protein interactions | Identify repressors such as Hmbox1 |
| Mass spectrometry | Crotonylation and other modifications | Post-translational control mapping |
| Glycogen synthesis assay | Downstream glucose storage | Functional readout of GCK activity |
| Live-cell imaging | Subcellular GCK localization | Nuclear export signal studies |
| CRISPR screening | Candidate negative regulators | Unbiased discovery of GCK repressors |
Enzyme activity assays
Glucokinase activity is measured by coupling glucose phosphorylation to NADPH production or by direct ATP consumption assays, allowing quantification of negative regulation in cell lysates [1, 7].
Transcriptional profiling
RNA-seq and qPCR quantify GCK mRNA and related transcriptional regulators such as KLF6, LXRalpha, SREBP-1c, PPARgamma, and SHP after genetic or pharmacological perturbation [2, 5].
Protein interaction and modification analysis
Immunoprecipitation, western blotting, and mass spectrometry detect GCK-interacting proteins such as Hmbox1 and post-translational modifications including crotonylation [1, 8].
Metabolic flux and imaging
Glucose uptake, glycogen synthesis, and live-cell imaging of fluorescent glucose analogs report the functional consequences of altered glucokinase regulation [3, 6].
How CRISPR Can Be Used to Study GO:0033132 negative regulation of glucokinase activity
Knockout
CRISPR knockout of candidate repressors such as Hmbox1 or KLF6 tests whether their loss increases glucokinase activity and downstream glucose metabolism [1, 2].
Point Mutation
Point-mutation knock-in of MODY2 variants in the GCK nuclear export signal or of phosphorylation sites allows precise testing of how single residues control glucokinase regulation [6, 8].
Knock-in
Tagged knock-in of endogenous GCK enables immunoprecipitation and imaging of the enzyme in its native regulatory context.
Overexpression
Overexpression of transcriptional repressors such as SHP or KLF6 tests whether increased repressor levels lower glucokinase activity and glucose phosphorylation [2, 5].
How EDITGENE Supports negative regulation of glucokinase activity Research
Researchers studying negative regulation of glucokinase activity-related genes often need to determine whether a candidate gene is causally involved in restraining GCK, or whether its effect is secondary to broader metabolic changes. EDITGENE provides the CRISPR tools and bioinformatics support to answer these questions rigorously.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glucokinase activity research.
Frequently Asked Questions About negative regulation of glucokinase activity
What is negative regulation of glucokinase activity?
It is the biological process GO:0033132, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of glucokinase activity, the ATP-dependent phosphorylation of glucose.
What genes are involved in negative regulation of glucokinase activity?
Genes include GCK itself, Hmbox1, KLF6, LXRalpha, SREBP-1c, PPARgamma, SHP, HNF4alpha, and PKCbeta [1, 2, 3, 5, 7].
How is glucokinase activity inhibited?
It can be inhibited transcriptionally by nuclear receptors and transcription factors, post-translationally by interacting proteins such as Hmbox1, and through modifications like crotonylation [1, 5, 8].
Why is glucokinase regulation important in liver disease?
Glucokinase links KLF6 to hepatic insulin sensitivity in nonalcoholic fatty liver disease, so its dysregulation contributes to impaired glucose handling.
What is the role of Hmbox1 in glucokinase regulation?
Hmbox1 restrains Gck activation in cardiomyocytes, and its inhibition promotes cardiomyocyte survival and glucose metabolism in ischemia/reperfusion injury.
How do MODY2 mutations affect glucokinase?
MODY2 mutations in the nuclear export signal of glucokinase alter its functional properties and cause monogenic diabetes.
Can berberine affect glucokinase activity?
Berberine modulates HNF4alpha expression and glucokinase activity in mouse primary hepatocytes.
What methods study negative regulation of glucokinase activity?
Glucokinase activity assays, RNA-seq, western blot, immunoprecipitation, mass spectrometry, and CRISPR screens are commonly used [1, 2, 5, 8].
What CRISPR models are used for glucokinase research?
Knockout, point-mutation knock-in, tagged knock-in, and overexpression models are used to test causal roles of GCK regulators [1, 6].
What is the GO ID for negative regulation of glucokinase activity?
The GO ID is GO:0033132, a biological_process term.
Conclusion
GO:0033132, negative regulation of glucokinase activity, is a biologically and clinically important process that controls glucose phosphorylation through transcriptional, post-translational, and compartmental mechanisms [1, 2, 5, 6]. Its dysregulation is linked to nonalcoholic fatty liver disease, MODY2 diabetes, and ischemia/reperfusion injury [1, 2, 6]. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with activity assays and bioinformatics, provide the tools needed to dissect these regulatory mechanisms and identify therapeutic targets [1, 6].
References
- 1. Bei Y et al.. 2024. Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury.. Circulation 150(11):848-866 PMID: 38708602
- 2. Bechmann LP et al.. 2012. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.. Hepatology 55(4):1083-93 PMID: 22095588
- 3. Shu Y et al.. 2021. Role of hepatic PKCβ in nutritional regulation of hepatic glycogen synthesis.. JCI Insight 6(19) PMID: 34622807
- 4. Swagell CD et al.. 2007. Regulation of human hepatocyte gene expression by fatty acids.. Biochem Biophys Res Commun 362(2):374-80 PMID: 17707340
- 5. Kim TH et al.. 2009. Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver.. J Biol Chem 284(22):15071-83 PMID: 19366697
- 6. Gutierrez-Nogués A et al.. 2018. Functional characterization of MODY2 mutations in the nuclear export signal of glucokinase.. Biochim Biophys Acta Mol Basis Dis 1864(7):2385-2394 PMID: 29704611
- 7. Yan ZQ et al.. 2008. [Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes].. Zhongguo Zhong Yao Za Zhi 33(18):2105-9 PMID: 19160796
- 8. Sun CF et al.. 2020. Crotonylation of key metabolic enzymes regulates carbon catabolite repression in Streptomyces roseosporus.. Commun Biol 3(1):192 PMID: 32332843
